Cargando…
Switching protease inhibitors to rilpivirine in HIV‐positive individuals with complete viral suppression and without prior HIV drug resistance in a resource‐limited setting: a randomized controlled trial
INTRODUCTION: Prior to the availability of rilpivirine (RPV), patients who could not tolerate efavirenz and nevirapine (NVP) were treated with protease inhibitor (PI)‐based antiretroviral therapy (ART). Dyslipidaemia and other metabolic complications are commonly associated with PI use. This study a...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150595/ https://www.ncbi.nlm.nih.gov/pubmed/32277868 http://dx.doi.org/10.1002/jia2.25462 |